Writing Group Disclosures
| Writing Group Member | Employment | Research Grant | Other Research Support |
Speakers’ Bureau /Honoraria |
Expert Witness | Ownership Interest | Consultant /Advisory Board |
Other |
|---|---|---|---|---|---|---|---|---|
| Alan S. Go | Kaiser Permanente | None | None | None | None | None | None | None |
| Emelia J. Benjamin | Boston University School of Medicine | NIH† | None | None | None | None | None | Associate Editor of Circulation |
| Jarett D. Berry | UT Southwestern | AHA†; NIH† | None | Merck† | None | None | None | None |
| William B. Borden | Weill Cornell Medical College/U.S. Department of Health and Human Services | None | None | None | None | None | None | None |
| Dawn M. Bravata | Department of Veteran Affairs | NIH/NHLBI† | None | None | None | None | None | None |
| Shifan Dai | Centers for Disease Control and Prevention | None | None | None | None | None | None | None |
| Earl S. Ford | Centers for Disease Control and Prevention | None | None | None | None | None | None | None |
| Caroline S. Fox | National Heart Lung and Blood Institute | None | None | None | None | None | None | None |
| Sheila Franco | Centers for Disease Control and Prevention/National Center for Health Statistics | None | None | None | None | None | None | None |
| Heather J. Fullerton | University of California, San Francisco | None | None | None | None | None | None | None |
| Cathleen Gillespie | Centers for Disease Control and Prevention | None | None | None | None | None | None | None |
| Susan M. Hailpern | Independent Consultant | None | None | None | None | None | None | None |
| John A. Heit | Mayo Clinic | None | None | None | None | None | Daiichi Sankyo*; GTC Biotherapeutics*; Janssen Pharmaceuticals* | None |
| Virginia J. Howard | University of Alabama at Birmingham | NIH† | None | None | None | None | None | None |
| Mark D. Huffman | Northwestern University Feinberg School of Medicine | NIH/NHLBI†; Scientific Therapeutic Information* | None | None | None | None | None | None |
| Brett M. Kissela | University of Cincinnati | None | None | None | None | None | None | None |
| Steven J. Kittner | University of Maryland School of Medicine | None | None | None | None | None | None | None |
| Daniel T. Lackland | Medical University of South Carolina | None | None | None | None | None | None | None |
| Judith H. Lichtman | Yale University | None | None | None | None | None | None | None |
| Lynda D. Lisabeth | University of Michigan | NHLBI; NINDS† | None | None | None | None | None | None |
| David Magid | Colorado Permanente Medical Group | None | None | None | None | None | None | None |
| Gregory M. Marcus | University of California, San Francisco | Forest Research Institute*; Gilead*; Medtronic*; SentreHeart†; Zoll* | None | St. Jude Medical* | None | None | None | None |
| Ariane Marelli | McGill University Health Center | None | None | None | None | None | None | None |
| David B. Matchar | Duke University Medical Center/Duke-NUS Graduate Medical School | None | None | None | None | None | AstraZeneca*; Boehringer Ingelheim* | None |
| Darren K. McGuire | UT Southwestern Medical Center | Boehringer Ingelheim*; Bristol-Meyers Squibb*; Daiichi Sankyo*; Eli Lilly*; Merck*; Orexigen†; Roche/Genentech*; Takeda* | None | None | Expert Witness for Takeda in class action suit for Actos* | None | Boehringer Ingelheim*; Daiichi Sankyo*; Genentech*; Janssen Pharmaceuticals†; Regeneron Pharmaceuticals*; Sanofi-Aventis* | None |
| Emile R. Mohler III | University of Pennsylvania | AHA†; Department of Defense†; NIH† | None | None | CytoVas*; FloxiMedical* | GlaxoSmithKline*; Merck*; Roche*; Takeda* | None | None |
| Claudia S. Moy | National Institutes of Health | None | None | None | None | None | None | None |
| Dariush L. Mozaffarian | Harvard School of Public Health/Brigham and Women’s Hospital/Harvard Medical School | NIH†; GlaxoSmithKline†; Pronova†; Sigma Tau† | None | Bunge*; International Life Sciences Institute*; Nutrition Impact*; Pollock Institute*; Sprim* | None | Harvard has filed a provisional patent application that has been assigned to Harvard, listing Dr. Mozaffarian as a co-inventor for use of trans-palmitoleic acid to prevent and treat insulin resistance, type 2 diabetes and related conditions*; Royalties from UpToDate for an online chapter* | Foodminds*; McKinsey Health Systems Institute*; Unilever North America* | None |
| Michael E. Mussolino | National Heart, Lung, and Blood Institute | None | None | None | None | None | None | None |
| Graham Nichol | University of Washington | None | None | None | None | None | None | None |
| Nina P. Paynter | Brigham and Women’s Hospital | Celera Corp.†; NHLBI†; NIH/NCRR† | None | None | None | None | None | None |
| Veronique L. Roger | Mayo Clinic | None | None | None | None | None | None | None |
| Pamela J. Schreiner | University of Minnesota | None | None | None | None | None | None | None |
| Paul D. Sorlie | National Heart, Lung, and Blood Institute, NIH | None | None | None | None | None | None | None |
| Joel Stein | Columbia University | Myomo, Inc.*; Tibion, Inc.*; Tyromotion, Inc.* | None | QuantiaMF* | None | None | Myomo, Inc.* | None |
| Tanya N. Turan | Medical University of South Carolina | NIH/NINDS† | None | None | None | None | None | None |
| Melanie B. Turner | American Heart Association | None | None | None | None | None | None | None |
| Salim S. Virani | Department of Veterans Affairs | Merck†; NFL Charities†; NIH†; VA† | None | None | None | None | None | None |
| Nathan D. Wong | University of California, Irvine | Bristol-Myers Squibb†; Merck† | None | None | None | None | Abbott Pharmaceuticals* | None |
| Daniel Woo | University of Cincinnati | NIH† | None | None | None | None | None | None |
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*
Modest.
†
Significant.